Although tiotropium numerically reduced exacerbations irrespective of concomitant ICS use or exacerbation history during the year preceding the trial, this reduction failed to reach statistical significance in those not receiving concomitant ICS or those with infrequent exacerbations in the preceding year.
← all excerpts
Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.
1
—
—